Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 5/20 | 0.45 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | IL6ST | P40189 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17241988 | 1.00 | IDH1 (0.45) | IDH1NAAAPOLBALDH1A1PPARA | |
| SCHEMBL8883087 | 1.00 | IDH1 (0.45) | IDH1NAAAPOLBALDH1A1PPARA | |
| SCHEMBL17241987 | 1.00 | IDH1 (0.45) | IDH1NAAAPOLBALDH1A1PPARA | |
| SCHEMBL2029159 | 0.89 | NAAA (0.46) | IDH1NAAAALDH1A1PPARAIL6ST | |
| SCHEMBL1049822 | 0.89 | NAAA (0.46) | IDH1NAAAALDH1A1PPARAIL6ST | |
| SCHEMBL1049820 | 0.89 | NAAA (0.46) | IDH1NAAAALDH1A1PPARAIL6ST | |
| SCHEMBL46343 | 0.87 | IDH1 (0.44) | IDH1NAAAPPARAIL6STFAAH | |
| SCHEMBL8555080 | 0.86 | NAAA (0.42) | IDH1NAAAALDH1A1PPARAIL6ST | |
| SCHEMBL4205626 | 0.86 | PPARA (0.44) | IDH1NAAAALDH1A1PPARAIL6ST | |
| SCHEMBL7066044 | 0.86 | PPARA (0.44) | IDH1NAAAALDH1A1PPARAIL6ST |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| EP-0848957-A1 | Fas LIGAND SOLUBILIZATION INHIBITOR | KANEBO LTD. (JP) | 1998-06-24 | — | — | EP | disclosed |
| CN-1110865-A | Amino acid derivatives | EISAI CO LTD (JP) | 1995-10-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | IDH1 1352/4885NAAA 1406/4885POLB 3124/4885 |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | IDH1 1352/4885NAAA 1406/4885POLB 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.